SEARCH PARAMETERS:
Therapy Line: Any
Cancer Type: Any
Clinic: Brooksville
Site Activity Name: 
Keywords:

BRE 260 - CP-MGAH22-04
A PHASE 3 RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS. TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT
Cancer types: Breast ER+, Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 274 - INO-VT-464-CL-006
A PHASE 1/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF SEVITERONEL IN SUBJECTS WITH ADVANCED BREAST CANCER
Cancer types: Breast ER+, Breast Triple Negative
Lines of therapy: 2nd Line Metastatic

CLL 39 - UTX-TGR-204
A MULTI-CENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF UBLITUXIMAB (TG-1101) IN COMBINATION WITH TGR-1202 FOR PATIENTS PREVIOUSLY ENROLLED IN PROTOCOL UTX-TGR-304
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 201 - GI 201
A PHASE II STUDY OF NAB-PACLITAXEL PLUS RAMUCIRUMAB FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC GASTROESOPHAGEAL CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 2nd Line Metastatic

GI 238 - CA209577
A RANDOMIZED MULTICENTER DOUBLE BLIND PHASE III STUDY OF ADJUVANT NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal
Lines of therapy: Adjuvant

GI 241 - CA209649
A RANDOMIZED MULTICENTER OPEN-LABEL PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB OR NIVOLUMAB IN COMBINATION WITH OXALIPLATIN PLUS FLUOROPYRIMIDINE VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 245 - ISB-MC-JGDP
A PHASE 2 (RANDOMIZED DOUBLE-BLINDED) STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 247 - CanStem303C
A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL LEUCOVORIN IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC)
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic
**GU 134 - WO30070**
A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPlatin VERSUS GEMCITABINE/CARBOPlatin ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GU 135 - MK-3475-361-00**
A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB WITH OR WITHOUT PLATINUM-BASED COMBINATION CHEMOTHERAPY VERSUS CHEMOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LUN 326 - CA209-384**
A DOSE FREQUENCY OPTIMIZATION TRIAL OF NIVOLUMAB 240 MG EVERY 2 WEEKS VS 480 MG EVERY 4 WEEKS IN ADVANCED OR METASTATIC NSCLC PATIENTS WHO RECEIVED 12 MONTHS OF NIVOLUMAB AT 3 MG/KG OR 240 MG EVERY 2 WEEKS

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, Other

**LYM 115 - BGB-3111-GA-101**
PHASE 1B STUDY TO ASSESS SAFETY, TOLERABILITY AND ANTITUMOR ACTIVITY OF THE COMBINATION OF BGB-3111 WITH OBINUTUZUMAB IN SUBJECTS WITH B-CELL LYMPHOID MALIGNANCIES

**Lines of therapy:** 2nd Line Metastatic

**LYM 120 - UTX-TGR-205**
A PHASE 2B RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION OF UBLITUXIMAB + TGR-1202 WITH OR WITHOUT BENDAMUSTINE AND TGR-1202 ALONE IN PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN'S LYMPHOMA.

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LYM 126 - PCYC-1141-CA**
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN TREATMENT NAIVE SUBJECTS WITH FOLLICULAR LYMPHOMA

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LUN 305 - D5164C00001**
PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291/PLACEBO IN PATIENTS WITH EGFR MUTATION POSITIVE STAGE IB-IIIA NSCLC FOLLOWING COMPLETE TUMOR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**MM 74 - NSMM-5001**
AN OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PARTICIPANTS

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

**MULTI 12 - CA209-627**
AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic
PRO 02 - ML28897
PHASE 2A STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB, AND VISMODEGIB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

PRO 10 - PRO 10
STUDY TO ASSESS THE ACTIVITY OF MOLECULARLY MATCHED TARGETED THERAPIES (REGORAFENIB OR AFATINIB) IN SELECT TUMOR TYPES BASED ON GENOMIC ALTERATIONS
Cancer types: Bladder, Esophogeal, Gastric, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Pancreas/Biliary, Solid Tumor
Lines of therapy: 2nd Line Metastatic

LYM 122 - ACE-LY-308
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF BR ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA.
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

MPN 09 - PAC203
AN OPEN-LABEL, RANDOMIZED, PHASE 2 DOSE-FINDING STUDY OF PACRITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB
Cancer types: Myelofibrosis
Lines of therapy: 2nd Line Metastatic

CLL 41 - TGR-1202-201
EVALUATE THE EFFICACY AND SAFETY OF TGR-1202 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO ARE INTOLERANT TO PRIOR THERAPY
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic

LUN 350 - B7461006
A STUDY OF LORLATINIB VERSUS CRIZOTINIB IN FIRST LINE TREATMENT OF PATIENTS WITH ALK-POSITIVE NSCLC
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 358 - D419MC00004
THIS IS A PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, COMPARATIVE GLOBAL PHASE 3 STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF DURVALUMAB OR DURVALUMAB + TREMELIMUMAB IN COMBINATION THERAPY WITH PLATINUM BASED CHEMOTHERAPY FOR THE FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC).
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

GYN 63 - PRO-105
A PHASE II OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF ACELARIN® (NUC-1031) GIVEN ON DAYS 1, 8 AND 15 OF A 28-DAY SCHEDULE IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
Cancer types: GYN
Lines of therapy: Other

BRE 296 - I3Y-MC-JPCF
A STUDY TO COMPARE TREATMENT AFTER SURGERY OF ABEMACICLIB (LY2835219) COMBINED WITH STANDARD ENDOCRINE THERAPY VERSUS ENDOCRINE THERAPY ALONE IN PARTICIPANTS WITH BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: Adjuvant
BRE 287 - H3B-6545-A001-101
A PHASE I-II MULTICENTER, OPEN LABEL TRIAL OF H3B-6545, A COVALENT ANTAGONIST OF ESTROGEN RECEPTOR ALPHA, IN WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 150 - CX-839-005
CB-839 WITH EVEROLIMUS VS. PLACEBO WITH EVEROLIMUS IN PATIENTS WITH RCC
Cancer types: Renal Cell
Lines of therapy: 3rd Line+ Metastatic

BRE 297 - MO39196
A STUDY OF ATEZOLIZUMAB AND PACLITAXEL VERSUS PLACEBO AND PACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 137 - E7080-G000-307
LENVATINIB/EVEROLIMUS OR LENVATINIB/PEMBROLIZUMAB VERSUS SUNITINIB ALONE AS TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Cancer types: Renal Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 362 - BO29554
A STUDY TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 304 - MO39193
A STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT TRIPLE-NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 303 - ODO-TE-B301
TESETAXEL PLUS REDUCED DOSE OF CAPECITABINE VS. CAPECITABINE IN HER2 NEGATIVE, HR POSITIVE, MBC
Cancer types: Breast ER+
Lines of therapy: Neo-Adjuvant, 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

LUN 371 - MK-3475-654
PEMBROLIZUMAB PLUS EPACADOSTAT VS. PEMBROLIZUMAB PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

LYM 135 - GO39942
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH R-CHP Versus RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced
LUN 372 - MK-3475-715
PEMBROLIZUMAB PLUS EPACADOSTAT ALONE OR WITH PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER
- **Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

GYN 78 - 3000-02-004
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY
- **Cancer types:** GYN
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

GI 258 - D419CC00002
STUDY OF DURVALUMAB AND TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
- **Cancer types:** Hepatocellular
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

MDS 21 - P-3001
PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PARTICIPANTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (AML)
- **Cancer types:** Hematology/Other, MDS, AML
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

LUN 380 - GO40920
A STUDY OF MTIG7192A IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAÏVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
- **Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

LUN 384 - CACZ88ST2301
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CANAKINUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN ADULT SUBJECTS WITH STAGES AJCC/UICC V. 8 II-IIIA AND IIIB (T>5CM N2) COMPLETELY RESECTED (R0) NON-SMALL CELL LUNG CANCER
- **Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous
- **Lines of therapy:** Adjuvant

GU 161 - CB-839-008
CB-839 WITH CABOZANTINIB VS. CABOZANTINIB WITH PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
- **Cancer types:** Renal Cell
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

MM 90 - EFC12522
RANDOMIZED, OPEN LABEL STUDY ASSESSING THE CLINICAL BENEFIT OF SAR650984, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE COMBINATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR TRANSPLANT
- **Cancer types:** Myeloma
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

GI 261 - CA209-9X8
AN INVESTIGATIONAL IMMUNOTHERAPY STUDY OF NIVOLUMAB WITH STANDARD OF CARE THERAPY VS STANDARD OF CARE THERAPY FOR FIRST-LINE TREATMENT OF COLORECTAL CANCER THAT HAS SPREAD
- **Cancer types:** Colorectal
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced
GI 268 - EF-27
EFFECT OF TUMOR TREATING FIELDS (TTFIELDS, 150 KHZ) AS FRONT-LINE TREATMENT OF LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA CONCOMITANT WITH GEMCITABINE AND NAB-PACLITAXEL
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 162 - D933C000003
STUDY OF DURVALUMAB ALONE AND DURVALUMAB+OLAPARIB IN ADVANCED, PLATINUM-INELIGIBLE BLADDER CANCER
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

LYM 145 - RP6530-1802
AN OPEN LABEL, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TENALISIB (RP6530), A NOVEL PI3K AK/AK DUAL INHIBITOR IN ADULT PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (INHL)
Cancer types: Lymphoma/Leukemia
Lines of therapy: 3rd Line+ Metastatic

GU 164 - 516-003
PHASE 2 STUDY OF SITRAVATINIB AND NIVOLUMAB IN ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Cancer types: Bladder
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MDS 24 - 04-30
CONTROLLED STUDY OF RIGOSERTIB VERSUS PHYSICIAN’S CHOICE OF TREATMENT IN MDS PATIENTS AFTER FAILURE OF AN HMA
Cancer types: Hematology/Other, MDS
Lines of therapy: 2nd Line Metastatic

LUN 396 - D9102C00001
STUDY OF DURVALUMAB+OLAPARIB OR DURVALUMAB AFTER TREATMENT WITH DURVALUMAB AND CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

LYM 148 - SGN35-027
A SAFETY STUDY OF GROWTH FACTOR USE IN TREATMENT WITH BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 322 - CLEE011012301C
A TRIAL TO EVALUATE EFFICACY AND SAFETY OF RIBOCICLIB WITH ENDOCRINE THERAPY AS ADJUVANT TREATMENT IN PATIENTS WITH HR+/HER2- EARLY BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: Adjuvant

GI 262 - CA025-006
A STUDY OF CABIRALIZUMAB GIVEN WITH NIVOLUMAB WITH AND WITHOUT CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy: 2nd Line Metastatic
MULTI 31 - 1381-0009
PLATFORM TRIAL EVALUATING SAFETY AND EFFICACY OF BI 754091 ANTI-PD-1 BASED COMBINATION THERAPIES IN PD-(L)1 NAIVE AND PD-(L)1 PRETREATED POPULATION WITH ADVANCED/METASTATIC SOLID TUMOURS.
Cancer types: Colorectal, Esophageal, Gastrointestinal, Head & Neck, Hepatocellular, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Pancreas/Biliary, Solid Tumor
Lines of therapy: 2nd Line Metastatic

LUN 398 - D9108C00002
NEOADJUVANT DURVALUMAB ALONE OR IN COMBINATION WITH NOVEL AGENTS IN RESECTABLE NON-SMALL CELL LUNG CANCER
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: Neo-Adjuvant

MDS 22 - ACE-536-002
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUZPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAIVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS THE "COMMANDS" TRIAL
Cancer types: Hematology/Other, MDS
Lines of therapy: Other

LUN 404 - Array 818-202
AN OPEN-LABEL STUDY OF ENCORAFENIB + BINIMETINIB IN PATIENTS WITH BRAFV600E-MUTANT NON-SMALL CELL LUNG CANCER
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

CLL 48 - BGB-3111-005
A STUDY OF ZANUBRUTINIB (BGB-3111) VERSUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 144 - UTX-TGR-203
PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB IN PATIENTS WITH TREATMENT NAIVE FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 402 - 516-005
PHASE 3 STUDY OF SITRAVATINIB PLUS NIVOLUMAB VS DOCETAXEL IN PATIENTS WITH ADVANCED NON-SQUAMOUS NSCLC
Cancer types: Lung NSCLC Non-Squamous
Lines of therapy: 2nd Line Metastatic

GU 156 - D8731C00001
A PHASE 2 OPEN-LABEL COMBINATION STUDY OF AZD4635 IN PATIENTS WITH PROSTATE CANCER
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 331 - ODO-TE-B202
PHASE 2 STUDY OF TESETAXEL PLUS THREE DIFFERENT PD-(L)1 INHIBITORS IN PATIENTS WITH TRIPLE-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER AND TESETAXEL MONOTHERAPY IN ELDERLY PATIENTS WITH HER2 NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Cancer types: Breast ER+, Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced
REFMAL 462 - PEN-221-001
PEN-221 IN SOMATOSTATIN RECEPTOR 2 EXPRESSING ADVANCED CANCERS INCLUDING NEUROENDOCRINE AND SMALL CELL LUNG CANCERS

Cancer types: Lung Small Cell, Neuroendocrine
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 29 - ML40053
A PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH NSCLC OR ADVANCED SOLID TUMORS THAT HAVE HAD PRIOR TREATMENT WITH A PD-1 INHIBITOR

Cancer types: Breast Triple Negative, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell, Solid Tumor, MSI High
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 320 - G1T48-01
PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF ASCENDING DOSES OF G1T48 IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER

Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

BRE 322 - D3614C00001
CAPIVASERTIB+PACLITAXEL AS FIRST LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TNBC

Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced

MULTI 35 - CV202-103
A STUDY OF BMS-813160 IN COMBINATION WITH CHEMOTHERAPY OR NIVOLOMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

Cancer types: Colo rectal, Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

BRE 329 - ODO-TE-B201
PHASE 2 STUDY OF TESETAXEL PLUS A REDUCED DOSE OF CAPECITABINE IN PATIENTS WITH HER2 NEGATIVE, HORMONE RECEPTOR POSITIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE NOT PREVIOUSLY RECEIVED A TAXANE

Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced

CLL 50 - BGB-3111-215
A STUDY OF ZANUBRUTINIB (BGB-3111) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA INTOLERANT OF PRIOR TREATMENT WITH IBRUTINIB

Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 170 - C3441021
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Cancer types: Prostate
Lines of therapy: 1st Line Metastatic - Locally Advanced

MULTI 50 - COO-388-180
A PHASE 2 MULTICENTER, OPEN-LABEL STUDY OF RUCAPARIB AS TREATMENT FOR SOLID TUMORS ASSOCIATED WITH DELETERIOUS MUTATIONS IN HOMOLOGOUS RECOMBINATION REPAIR GENES

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colo rectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Pancreas/Biliary, Prostate, Solid Tumor, BRCA mutated, ovarian, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

Created on 2/1/2020 at 0:8 AM
**LUN 413 - AB928CSP0004**

**STUDY TO EVALUATE IMMUNOTHERAPY COMBINATIONS IN PARTICIPANTS WITH LUNG CANCER**

- **Cancer types:** Lung NCSLC Non-Squamous
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

---

**BRE 336 - TAS-120-201**

**PHASE 2 STUDY OF TAS-120 IN METASTATIC BREAST CANCERS HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) AMPLIFICATIONS**

- **Cancer types:** Breast ER+
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

---

**GI 286 - D933AC00001**

**PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-REGIONAL, INTERNATIONAL STUDY OF DURVALUMAB IN COMBINATION WITH GEMCITABINE PLUS CISPLATIN VERSUS PLACEBO IN COMBINATION WITH GEMCITABINE PLUS CISPLATIN FOR PATIENTS WITH FIRST-LINE ADVANCED BILIARY TRACT CANCERS**

- **Cancer types:** Pancreas/Biliary
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

---

**LUN 407 - J2G-MC-JZJC**

**A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND Pemetrexed THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER**

- **Cancer types:** Lung NCSLC Non-Squamous
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced